Eli Lilly, a leading American pharmaceutical company, has launched its groundbreaking diabetes and obesity medication, Mounjaro (tirzepatide), in India. This development comes as a response to the rising cases of diabetes and obesity in the country, offering an advanced treatment option for patients struggling with these conditions.
Pricing and Availability
In India, Mounjaro is available in single-dose vials at the following prices:
-
2.5 mg vial – ₹3,500
-
5 mg vial – ₹4,375
Since Mounjaro is a once-weekly injectable medication, the monthly treatment cost varies between ₹14,000 and ₹17,500, depending on the prescribed dosage. This pricing is significantly lower than in the United States, where a monthly supply costs between $1,000 and $1,200. By offering the drug at a fraction of the price, Eli Lilly aims to make this innovative treatment more accessible to Indian patients.
How Mounjaro Works
Mounjaro functions as a dual-acting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This means it:
-
Enhances insulin secretion
-
Reduces glucagon release
-
Slows down gastric emptying
These combined effects lead to better blood sugar control and significant weight loss, making Mounjaro an effective option for individuals dealing with both diabetes and obesity.
Competition and Market Impact
Eli Lilly’s launch of Mounjaro puts it ahead of competitors in India’s growing market for diabetes and obesity treatments. Novo Nordisk, another major pharmaceutical company, plans to introduce its weight-loss drug Wegovy in India by 2026. Additionally, several Indian pharmaceutical companies, including Sun Pharmaceutical, Biocon, Zydus Lifesciences, Cipla, Dr. Reddy’s, Lupin, Natco Pharma, Mankind Pharma, and Aurobindo Pharma, are working on developing generic versions of GLP-1 receptor agonists.
Given the increasing demand for obesity treatments in India, the introduction of such medications will likely intensify competition, ultimately benefiting patients by providing more treatment options at competitive prices.
A Game-Changer for Public Health
The launch of Mounjaro marks a significant advancement in the management of diabetes and obesity in India. By targeting both GIP and GLP-1 receptors, this drug provides a more comprehensive approach to these conditions. With more pharmaceutical companies expected to enter this market, Indian patients can anticipate better accessibility, improved treatment choices, and potentially enhanced health outcomes.
The availability of Mounjaro at a lower cost compared to global prices is a step toward making life-changing medications more affordable for Indian consumers. As the market for diabetes and obesity treatments evolves, patients will benefit from increasing innovations, improved drug efficacy, and competitive pricing, helping them achieve better health and quality of life.
